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Topotecan is a topoisomerase 1 (TOP1) inhibitor that is used to
treat various forms of cancer. We recently found that topotecan
reduces the expression of multiple long genes, including many
neuronal genes linked to synapses and autism. However, whether
topotecan alters synaptic protein levels and synapse function is
currently unknown. Here we report that in primary cortical neurons,
topotecan depleted synaptic proteins that are encoded by ex-
tremely long genes, including Neurexin-1, Neuroligin-1, Cntnap2,
and GABAAβ3. Topotecan also suppressed spontaneous network
activity without affecting resting membrane potential, action po-
tential threshold, or neuron health. Topotecan strongly suppressed
inhibitory neurotransmission via pre- and postsynaptic mechanisms
and reduced excitatory neurotransmission. The effects on synaptic
protein levels and inhibitory neurotransmissionwere fully reversible
upon drug washout. Collectively, our findings suggest that TOP1
controls the levels of multiple synaptic proteins and is required for
normal excitatory and inhibitory synaptic transmission.
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Topoisomerase inhibitors such as topotecan (Hycamtin) arewidely used to treat multiple forms of cancer, including brain
metastases, ovarian cancer, and small cell lung cancer (1). Topo-
isomerases resolve DNA supercoiling during cell division and
during gene transcription (2). Type I topoisomerases, encoded by
Top1, Top3a, and Top3b in mammals, resolve supercoiling by
cleaving a single strand of DNA, whereas type II topoisomerases,
encoded by Top2a and Top2b, cleave both DNA strands (2).
Recently, both types of topoisomerases were associated with
neurodevelopment (3–5). For instance, topoisomerase 1 (TOP1)
and topoisomerase 2 (TOP2) inhibitors transcriptionally up-reg-
ulate the paternal copy of Ubiquitin-protein ligase E3A (Ube3a)
(5), a gene that affects synaptic activity and that is deleted or
duplicated in distinct neurodevelopmental disorders (Angelman
syndrome and autism, respectively) (6, 7). Moreover, a de novo
mutation in Top1 and de novo mutations in genes that interact
with Top1 and Top3b were identified recently in patients with
autism (8, 9), whereas deletion of Top3b increases the risk for
schizophrenia and intellectual disability (10, 11). Top2b is also
required for axon outgrowth in different regions of the nervous
system and for the survival of postmitotic neurons (12–15).
TOP1 is localized primarily in the nucleus of postmitotic
neurons and is expressed throughout the developing and adult
brain (16), suggesting a nuclear function. Indeed, we recently
found that topotecan, a selective TOP1 inhibitor, reduced the
expression of extremely long genes (>200 kb) in postmitotic
neurons by impairing transcription elongation (17). Topotecan
and related camptothecin analogs inhibit TOP1 by covalently
trapping the enzyme on DNA (2). TOP1 inhibitors also reduce
the expression of long genes in cancer cell lines (17–19), re-
vealing a gene length-dependent component to transcription that
is common to several mammalian cell types.
In neurons, many genes down-regulated by topotecan are as-
sociated with synapses, cell adhesion, and neurotransmission
(17). Moreover, a number of these down-regulated long genes
are associated with autism, including Neurexin-1 (Nrxn1; 1,059
kb), Neuroligin-1 (Nlgn1; 900 kb), and Contactin-associated pro-
tein 2 (Cntnap2; 2,241 kb), genes that are well known to regulate
inhibitory and excitatory synaptic function (20–22). In contrast,
topotecan had minimal effects on most other genes expressed in
neurons (the average length of expressed genes in mouse neu-
rons is 59.3 kb) (17).
Because the transcriptional effects following TOP1 inhibition
were strongly biased toward long, synapse-associated genes, we
hypothesized that TOP1 might be particularly important for
maintaining normal synaptic functions (17). In this study we tested
this hypothesis using biochemical and physiological approaches
with cultured mouse cortical neurons. We found that multiple
synaptic proteins, each encoded by extremely long genes, were
depleted after neurons were treated with topotecan, a TOP1 in-
hibitor. TOP1 inhibition also profoundly suppressed excitatory
and inhibitory synaptic activity without affecting overall neuron
health. Our study shows that TOP1 regulates the levels of multiple
synaptic proteins and is required for proper synaptic function.
Moreover, our work provides insights into how TOP1 dysfunction
could impact synaptic activity.
Results
Depletion of Synaptic Cell Adhesion Proteins That Originate from
Long Genes. NRXN1 and NLGN1 are well-characterized synap-
tic adhesion molecules that interact with each other on opposing
sides of the synaptic terminal (Fig. 1 A and B) (21, 23) and are
encoded by extremely long genes (17). We previously found that
topotecan, a selective TOP1 inhibitor, dose-dependently reduced
the expression of Nrxn1 and Nlgn1, as well as many other long
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autism- and synapse-associated genes (17). To determine if
topotecan reduces the protein levels of NRXN1 and NLGN1, we
treated cultured cortical neurons at 7 d in vitro (DIV 7) with
vehicle or 300 nM topotecan and then harvested cells at various
time points for Western analyses. We detected multiple NRXN1
bands in vehicle-treated samples (Fig. 1C), consistent with there
being multiple NRXN1 isoforms (21, 24). After topotecan was
added, NRXN1 levels declined within 24 h and remained low
when exposed to drug for 72 h (Fig. 1 C and E). Likewise,
NLGN1 levels declined in topotecan-treated neurons and
remained low when exposed to drug for 72 h (Fig. 1 D and F).
The protein level of CNTNAP2, another synaptic adhesion
molecule that is encoded by an extremely long gene (17), also
was depleted in topotecan-treated neurons (Fig. 1 G and H).
In contrast, postsynaptic density protein 95 (PSD95, DLG4;
gene length, 26.9 kb), a scaffolding protein that interacts with
NLGN1 (25), was slightly elevated at the 72-h time point (Fig. 1
G and H). We did not examine NLGN2 or NLGN3 because the
expression of these short genes (14.6 kb and 26.1 kb, respectively)
was not altered in topotecan-treated neurons (17). Consistent
with previous work, topotecan increased protein levels of UBE3A
(Fig. 1 G and H) by reducing the expression of an extremely long
antisense transcript that overlaps Ube3a (5, 17).
Prolonged treatment (up to 7 d) with topotecan did not alter
MAP2 staining or activate caspase-3 (Fig. S1), a marker of ap-
optotic cells; this result is consistent with our previous finding
showing that 300 nM topotecan is not toxic to neurons (17). As
positive controls, a high concentration of topotecan (10 μM) or
glutamate (250 μM) resulted in disorganized MAP2 staining and
activated caspase-3 (Fig. S1).
Taken together, these experiments show that three synaptic
adhesion molecules, each originating from extremely long genes,
are depleted with a drug that inhibits TOP1. This finding is
noteworthy, given that mutations in any one of these long genes
can impair synaptic function and neurodevelopment (21, 26, 27).
TOP1 Inhibition Suppresses Spontaneous Network Activity in Cortical
Neurons. Because the expression of Nrxn1, Nlgn1, Cntnap2, and
other genes linked to synaptic function was reduced in topo-
tecan-treated neurons (17), we hypothesized that topotecan
might impair synaptic activity in neuronal cultures. To test this
hypothesis, we took advantage of the fact that after approxi-
mately 2 weeks in culture (on DIV 14–15) cortical neurons
generate spontaneous, synchronous bursts of electrical activity
that can be monitored with Ca2+-sensitive dyes or by whole-cell
electrophysiology (28–32). Because bursting begins after about 2
weeks, we delayed the addition of topotecan from DIV 7–10 to
DIV 11–14. Importantly, NRXN1 and NLGN1 protein levels
were decreased to a similar extent regardless of whether cultures
were treated with topotecan from DIV 7–10 (Fig. 1 C–F) or from
DIV 11–14 (Fig. S2 A–D). Using the ratiometric Ca2+ indicator
fura-2, we found that vehicle-treated cultures displayed synchro-
nous, low-amplitude Ca2+ bursts (R340/380: 0.032 ± 0.001) with
a frequency of 2.0 ± 0.6 bursts/min (Fig. 2 A, B, and D and Movie
S1). The addition of gabazine (GBZ), a GABAA receptor antago-
nist, increased the amplitude of these Ca2+ bursts (R340/380: 0.328 ±
0.005) without changing burst frequency (1.9 ± 0.7 bursts/min) (Fig.
2 A, B, and D and Movie S1). Coapplication of GBZ and 6,7-
dinitroquinoxaline-2,3-dione disodium salt (DNQX), an AMPA-
type glutamate receptor antagonist, eliminated these bursts (Fig.
2B). In contrast, no Ca2+ bursts were detected in most cultures
treated with topotecan for 72 h [six of six cultures in artificial
cerebrospinal fluid (ACSF); five of six cultures in ACSF+GBZ]
(Fig. 2 C and D and Movie S2). The nearly complete loss of ac-
tivity was not caused by compromised neuronal health or overt
impairment of voltage-gated calcium channels, because vehicle
and topotecan-treated neurons displayed equivalent calcium
responses following KCl-induced depolarization (Fig. 2B, Fig.
S2E, and Movies S1 and S2).
We also monitored synchronous bursts of activity in vehicle-
and topotecan-treated cultures by whole-cell recordings (all ac-
tivity was eliminated when GBZ and tetrodotoxin were added)
(Fig. S3 A–E). Consistent with our Ca2+ imaging results, topo-
tecan (300 nM) significantly reduced burst activity in ACSF and
GBZ conditions (Fig. 2 E and F and Fig. S3 F–H). Based on
cumulative distribution analyses, no bursts were observed during
the recording session in a large percentage of topotecan-treated
cultures (Fig. S3H). In contrast, bursts were detected in the
majority of vehicle-treated cultures. Taken together, these data
indicate that topotecan suppresses spontaneous synaptic activity
without affecting neuron health and suggests a role for TOP1 in
maintaining neurotransmission at normal levels.
TOP1 Inhibition Impairs Excitatory Synapse Formation and Function.
TOP1 is well positioned to regulate gene expression in excitatory
and inhibitory neurons, because TOP1 is present in 93% of all
NeuN+ neurons in culture, including 99% of all MAP2+ neu-
rons and 100% of all glutamic acid decarboxylase 67-positive
(GAD67+) inhibitory neurons (Fig. S4). To provide insights into
how TOP1 inhibition affects network activity, we examined in-
trinsic electrical properties and miniature excitatory postsynaptic
currents (mEPSCs) in GAD67− pyramidal neurons and GAD67+
interneurons (see SI Materials and Methods for details of cell
classification). We found that mEPSCs were undetectable until
DIV 11 in cultured mouse cortical neurons, analogous to others’
observations in rat neurons (33), so we extended the topotecan
treatment by an additional 1–4 days. Note that over this longer
time course NRXN1 and NLGN1 protein levels remained low
Fig. 1. TOP1 inhibition reduces the expression of synaptic adhesion mole-
cules. (A and B) Schematics of an excitatory (A) and inhibitory (B) synapse.
Pre, presynaptic; Post, postsynaptic. (C and D) Cortical neurons were treated
with vehicle or with 300 nM topotecan on DIV 7 and then were harvested 4,
8, 24, 48, or 72 h later. Shown are representative immunoblots with anti-
bodies to NRXN1 (C) or NLGN1 (D) and actin. (E and F) Quantification of fold
change in NRXN1 (E) and NLGN1 (F) expression normalized to actin. Data are
shown as means ± SEM; n = 3 cultures. *P < 0.05 (unpaired Student t test). (G
and H) Cortical neurons were treated with vehicle or 300 nM topotecan from
DIV 7–10 and then were harvested for Western blot analysis. (G) Shown are
representative immunoblots of the indicated proteins. (H) Fold change of
the indicated proteins, normalized to actin. Data are shown as means ± SEM;
n = 4–6 cultures. *P < 0.05, **P < 0.005 (unpaired Student t test).








(Fig. S5 A–D) without affecting cell health (Fig. S1). We ob-
served no significant differences in the resting membrane po-
tential or action potential threshold in pyramidal neurons or
inhibitory neurons (Fig. S5E). However, there was a significant
increase in input resistance and a significant reduction in mem-
brane capacitance and rheobase in pyramidal neurons but not in
inhibitory neurons (Fig. S5E). These data suggest that topotecan-
treated pyramidal neurons are more excitable. However, increased
pyramidal neuron excitability would be predicted to increase net-
work activity, not reduce network activity as we observed.
Thus we next explored the possibility that TOP1 inhibition
reduced synaptic activity. To test this possibility, we treated
neurons with topotecan on DIV 7 and then recorded mEPSCs on
DIV 11–13. We found that treatment of cortical neurons with
topotecan decreased mEPSC frequency but not mEPSC ampli-
tude in pyramidal neurons (Fig. 3 A–C). In the interneuron
population, topotecan strongly decreased both mEPSC ampli-
tude and frequency (Fig. 3 D–F). Moreover, topotecan reduced
the number of excitatory synapses, as evidenced by fewer vesic-
ular glutamate transporter 1 (VGLUT1, a presynaptic marker)
puncta and fewer VGLUT1/PSD95 colocalized puncta in topo-
tecan-treated neurons (Fig. 3 G–I). There was no change in the
number of PSD95 (a postsynaptic marker) puncta (Fig. 3H). We
were unable to measure a change in the probability of neuro-
transmitter release at excitatory synapses because in vehicle-
treated cultures electrical stimulation evoked a barrage of poly-
synaptic activity that obscured the monosynaptically evoked
events. Taken together, these data suggest that TOP1 activity is
required for the formation and function of excitatory synapses.
TOP1 Inhibition Profoundly Impairs Inhibitory Synapse Function
Without Affecting Inhibitory Synapse Number. Next, we examined
how TOP1 inhibition affects inhibitory synapses by measuring
miniature inhibitory postsynaptic currents (mIPSCs) in GAD67–
pyramidal neurons and GAD67+ interneurons. We found that
mIPSC amplitude and frequency were profoundly reduced in
pyramidal neurons and interneurons in topotecan-treated cul-
tures (Fig. 4 A–F). Additionally, we examined release probability
by testing the paired-pulse ratio of evoked IPSCs (Fig. 4 G and
H). Topotecan-treated neurons had higher paired-pulse ratios at
50-ms, 100-ms, and 1-s interstimulus intervals (ISIs), suggesting
a decrease in the probability of neurotransmitter release.
To determine if these effects on inhibitory synapse activity were
associated with a reduction in the number of inhibitory synapses, we
immunostained for the inhibitory postsynaptic marker GEPHYRIN
and the inhibitory presynaptic marker vesicular GABA transporter
(VGAT) (Fig. S6A). There was no significant change in the number
of GEPHYRIN, VGAT, or colocalized VGAT/GEPHYRIN
puncta (Fig. S6 A–C), indicating that TOP1 inhibition did not
alter the number of inhibitory synapses.
GABAA receptors mediate synaptic transmission at many in-
hibitory synapses (34). We previously found that the expression
of the GABAAβ1 and GABAAβ3 receptor subunits was reduced
in topotecan-treated cortical neurons (17). These GABAA re-
ceptor subunits are encoded by long genes (437.2 kb and
238.3 kb, respectively). Because spontaneous mIPSC amplitude
was reduced in topotecan-treated neurons, we next explored the
possibility that overall GABAA receptor levels were reduced in
topotecan-treated neuronal cultures. Based on Western blot
Fig. 2. TOP1 inhibition suppresses spontaneous calcium bursts and electrical
activity in cortical neuron cultures. Fura2-calcium imaging of spontaneous
network activity in neurons at DIV 14–15 after the addition of 5 μM GBZ,
after the addition of GBZ plus 5 μM DNQX, and after all neurons were
depolarized with 55 mM KCl. (A) Representative images from vehicle-treated
neurons taken at time points 1–6 indicated in B. (B) Activity in neurons
treated with vehicle (Veh.). (C) Activity in neurons treated with 300 nM
topotecan (Topot.) at 72 h. (D) Ca2+ burst frequency. Data are shown
as means ± SEM from three independent cultures; n = 6–8 coverslips per
condition; n = 466 neurons for vehicle treatment, and n = 280 neurons for
topotecan treatment. *P < 0.05, **P < 0.005 (unpaired Student t test). (E and
F) Spontaneous burst activity monitored by whole-cell electrophysiology in
cortical neuron cultures treated with vehicle (black trace) or 300 nM topo-
tecan (red trace). Treatment started on DIV 7 and ended on the day of
recording. (E) Representative voltage-clamp recordings in ACSF and after
the addition of 5 μM GBZ. (F) Burst frequency integrated from DIV 10–14.
***P < 0.0005 (significantly different from vehicle by Mann–Whitney test).
Fig. 3. TOP1 inhibition impairs excitatory synaptic transmission and synapse
formation. (A–C) Pyramidal neurons were treated with vehicle or 300 nM
topotecan beginning on DIV 7 and ending on the day of recording (DIV 11–13).
(A) Representative mEPSC traces. (B) mEPSC amplitude (Left) and frequency
(Right). *P < 0.05 (Mann–Whitney test); n.s., not significantly different. (C)
Cumulative distribution of mean mEPSC amplitudes (Left) and frequencies
(Right). (D–F) Interneurons were treated with vehicle or 300 nM topotecan
starting on DIV 7 and ending on the day of recording (DIV 11–13). (D) Rep-
resentative mEPSC traces. (E) mEPSC amplitude (Left) and frequency (Right).
***P < 0.0005, *P < 0.05 (Mann–Whitney test). (F) Cumulative distribution of
mean mEPSC amplitudes (Left) and frequencies (Right). (G–I) Cortical neuron
cultures were infected with GFP lentivirus on DIV 3. Neurons then were treated
with vehicle or 300 nM topotecan for 72 h, beginning on DIV 7. (G) On DIV 10,
neurons were immunostained for VGLUT1 (an excitatory presynaptic marker),
PSD95 (an excitatory postsynaptic marker), and GFP. (Scale bars, 10 μm.) (H)
Number of PSD95 and VGLUT1 puncta per 50 μm of dendrite. n = 33 (Veh.), 37
(Topot.) neurons. *P < 0.05 (unpaired Student t test). (I) Number of colocalized
VGLUT1/PSD95 puncta per 50 μm of dendrite. Data in B, E, H, and I are pre-
sented as means ± SEM. *P < 0.05 (unpaired Student t test).
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analysis from whole-cell lysates, we found that the GABAA re-
ceptor subunits GABAAβ3 and GABAAγ2 were reduced at the
protein level following TOP1 inhibition (Fig. S6 D–G). GABAAβ1
was reduced at the transcript level (17) but not at the protein level,
possibly reflecting a longer protein half-life (35).
GABAA receptors are pentameric receptors made up of mul-
tiple subunits (34). Disruption of individual GABAA receptor
subunits can reduce the surface levels of interacting subunits (36,
37). To determine if TOP1 inhibition altered the surface levels of
multiple GABAA receptor subunits, we labeled surface GABAA
receptors with biotin and then quantified surface and total pro-
tein levels. We found that TOP1 inhibition reduced the surface
expression of GABAAβ3, GABAAγ2, and GABAAα1 (Fig. S6 H
and I), subunits that are expressed in cortical neurons at this
developmental age (38). We were unable to detect surface ex-
pression of the GABAAβ1 subunit, possibly because it is not
trafficked to the membrane or incorporated into GABAA re-
ceptors at this stage of development. Additionally, we did not
observe a change in GABAAα5 subunit levels (Fig. S6 H and I).
Taken together, our data indicate that TOP1 inhibition de-
creased neurotransmission at inhibitory synapses without changing
the number of inhibitory synapses. Moreover, our data suggest
that deficits in neurotransmitter release probability and post-
synaptic GABAA receptor density could account for reduced in-
hibitory synapse function.
Synaptic Effects of Topotecan Are Reversible. We previously found
that the genomewide transcriptional effects of topotecan were
fully reversible upon drug washout (17), suggesting that the syn-
aptic phenotypes caused by TOP1 inhibition also might be re-
versible. To test this possibility, we treated neurons on DIV 7 with
topotecan for 72 h, washed out the drug, and then assessed re-
covery 24–72 h later. As above, topotecan reduced the levels of
NRXN1, NLGN1, and GABAAβ3 at the 72-h time point (Fig. 5 A
and B). Remarkably, the levels of all these proteins were restored
to pretreatment levels or higher upon drug washout. GABAAβ3
levels were higher at the 72-h time point in both vehicle- and
topotecan-treated neurons, most likely because the expression of
Fig. 4. Topotecan suppresses inhibitory synaptic transmission. (A–C) Pyra-
midal neurons were treated with vehicle or 300 nM topotecan starting on
DIV 7 and ending on the day of recording (DIV 10–14). (A) Representative
mIPSC traces. (B) mIPSC amplitude (Left) and frequency (Right). ***P <
0.0005 (Mann–Whitney test). (C) Cumulative distribution of mean mIPSC
amplitudes (Left) and mIPSC frequencies (Right). (D–F) Interneurons were
treated with vehicle or 300 nM topotecan starting on DIV 7 and ending on
the day of recording (DIV 10–14). (D) Representative mIPSC traces. (E) mIPSC
amplitude (Left) and frequency (Right). ***P < 0.0005 (Mann–Whitney test).
(F) Cumulative distribution of mean mIPSC amplitudes (Left) and mIPSC
frequencies (Right). (G) Representative traces of evoked IPSCs at different
ISIs from cultured cortical neurons treated with vehicle or 300 nM topotecan.
Treatment started on DIV 7 and ended on the day of recording (DIV 10–14).
Glutamatergic transmission was blocked with DNQX and D-2-amino-5-phos-
phonovaleric acid (DL-AP5). Stimulus artifacts have been erased for clarity.
(H) Paired-pulse ratios for bursts elicited at 50-ms, 100-ms, and 1-s ISIs. *P <
0.05, **P < 0.005, ***P < 0.0005 (Mann–Whitney test). The number of
neurons recorded is indicated in graphs. Data in B, E, and H are presented as
means ± SEM.
Fig. 5. Effects of TOP1 inhibition on synaptic protein levels and synaptic
transmission are reversible following topotecan washout. (A and B) Beginning
on DIV 7, cortical neurons were treated for 72 h with vehicle or 300 nM topo-
tecan. Topotecan was washed out, conditioned medium was added, and
neurons were harvested 24 (DIV 11), 48 (DIV 12), or 72 (DIV 13) h later. (A)
Representative immunoblots for the indicated proteins. (B) Quantification of
fold change in protein levels normalized to tubulin or actin. n = 3–6 culture
wells. **P < 0.005, ***P < 0.0005 (unpaired Student t test). (C–G) Neurons were
treated with vehicle or 300 nM topotecan for 72 h. Topotecan was washed out
72 h later (on DIV 10) (blue trace and bars), and neurons were recorded 48 h
(DIV 12), 72 h (DIV 13), and 4 d (DIV 14) later. Alternatively, neurons were kept
in medium containing vehicle (black trace and bars) or topotecan (red trace
and bars) until recording. (C) Representative mIPSC traces on DIV 13. (D and E)
mIPSC amplitude (D) and frequency (E) from 48 h (DIV 12; n = 24, 22, 23), 72 h
(DIV 13; n = 22, 22, 19), and 4 d (DIV 14; n = 15, 21, 21) of drug washout. (F and
G) mIPSC amplitude (F, Left), frequency (G, Left), and cumulative distribution
data (F and G, Right) averaged across DIV 12–14. *P < 0.05, **P < 0.005, ***P <
0.0005 (Mann–Whitney test). Data in B and D–G are presented asmeans ± SEM.








this subunit increases over time in culture (38). Additionally, the
profound reduction in mIPSC amplitude and frequency in topo-
tecan-treated pyramidal neurons was restored within 48 h of drug
washout (Fig. 5 C–G), paralleling the biochemical recovery of
NRXN1, NLGN1, and GABAAβ3 (Fig. 5 A and B). Taken to-
gether, our data indicate that the transcriptional, posttranscrip-
tional, and synaptic deficits in topotecan-treated neurons are directly
correlated and are all fully reversed upon drug washout, thus
suggesting that TOP1 is required in these processes.
Discussion
We previously found that TOP1 inhibitors reduce the expression
of a large number of long genes linked to synapses and to autism
(17). However, whether TOP1 inhibitors affect synaptic protein
levels or synaptic function was unknown. Here, we report that
multiple synaptic proteins encoded by long genes, including cell
adhesion molecules linked to autism and GABA receptor
subunits, are depleted in topotecan-treated neurons. These find-
ings suggest that TOP1 inhibitors could reduce the protein levels
of many genes with long transcripts (17), especially if their protein
half-lives are relatively short (35). Moreover, our data suggest that
a basic biological feature—gene length—can be used to predict
whether TOP1 inhibitors will reduce gene expression and protein
levels. Thus, neurons appear to have an Achilles heel in the form
of TOP1, because inhibition of this single transcriptional regulator
depletes multiple proteins required for normal synaptic function.
Remarkably, spontaneous burst activity was eliminated al-
most completely in topotecan-treated cultures. Burst activity
presumably was shaped by GABAA and glutamate receptor ac-
tivation, because bursts were sensitive to antagonists of these
receptors, consistent with previous studies (28–32). Inhibition of
TOP1 also profoundly impaired inhibitory synaptic activity
without affecting the number of inhibitory synapses or neuron
health, as measured by the absence of caspase-3 activation and
the lack of effect on depolarization-induced (voltage-gated)
calcium influx. Given that the loss and restoration of transcripts,
synaptic proteins, and synaptic function were coincident, our
data suggest that TOP1 serves as a master transcriptional regu-
lator for many synaptic proteins and for synaptic function.
Because TOP1 inhibition affects multiple synaptic proteins, it
was not possible to predict a priori how deficits in synaptic
transmission would manifest. Intriguingly, some of the pheno-
types observed with topotecan bear similarities to knockdown or
KO models for NRXN1, NLGN1, and CNTNAP2. For instance,
in neocortex, Nrxn1α-KO mice exhibit synaptic deficits, such as
a decrease in mIPSC frequency (39). Moreover, Nrxn1α/2α dou-
ble-knockout mice have decreased neurotransmitter release,
which is similar to our findings at inhibitory synapses (39). Al-
though synaptic transmission and synapse number in NLGN1-KO
mice are phenotypically normal (40–42), shRNA knockdown of
NLGN1 decreases the number of excitatory and inhibitory syn-
apses in hippocampal neuron culture (43). Additionally, sparse
knockdown of NLGN1 in a subset of neurons in utero leads to
decreases in mEPSC frequency (44). Moreover, in a culture sys-
tem similar to ours, Südhof and colleagues found that excitatory
and inhibitory neurotransmission were reduced after knockdown
of Cntnap2 (32), a long gene whose protein levels are reduced
upon TOP1 inhibition (Fig. 1 G and H). Thus, depending on the
system, brain region, and the context of the reduction/deletion,
NRXN1, NLGN1, and CNTNAP2 can have varying effects on
synaptic transmission, and some of these effects phenocopy our
findings in topotecan-treated cortical neurons.
We previously found that the transcriptional effects of topotecan
on long synaptic genes were dose dependent (17). Given these
graded transcriptional effects, synaptic function and brain de-
velopment are likely to be impacted in proportion to how strongly
TOP1 is inhibited by chemicals or mutations. Moreover, TOP1
activity increases from birth to maturity (16) and can be inhibited
by the activation of glutamate or GABA receptors in mouse cer-
ebellum (45). Thus, several mechanisms may regulate the tran-
scriptional activities of TOP1 in neurons in a graded manner.
Because the expression of multiple long synaptic genes was
reduced in topotecan-treated neurons, it seems unlikely that
adding back one of these down-regulated genes (such as Nrxn1)
would fully rescue synaptic deficits. Moreover, adding back one
synaptic cell-adhesion molecule would not likely restore the
protein levels of all affected synaptic cell-adhesion molecules as
well as multiple GABAA receptor subunits. Note that we were
unable to rescue phenotypes in topotecan-treated neurons ge-
netically because TOP1, when overexpressed, was just as sensi-
tive to topotecan as endogenous TOP1.
Our study was focused on using topotecan, a drug that poisons
and depletes TOP1 protein (2, 5). Irinotecan (used to treat gas-
trointestinal malignancies) (1) is another TOP1 inhibitor derived
from camptothecin, and ICRF-193 is a TOP2 inhibitor. Both drugs
had transcriptional effects in neurons similar to those of topotecan
(17). Thus, we speculate that other drugs that inhibit TOP1 or
TOP2 enzymes could have similar effects on synapse function.
Our findings in mammalian neurons may have parallels to re-
search with TOP1 in Drosophila. TOP1 deletion is lethal in flies
and mice (46, 47). However, a mutation that reduced TOP1 ex-
pression in the fly brain was not lethal and suppressed seizure-like
behavior (47). Feeding flies TOP1 inhibitors, including campto-
thecin (a derivative of topotecan) and apigenin (a flavone found in
fruits and vegetables) also suppressed seizures (48). Mechanisti-
cally how TOP1 inhibition blocked seizures in flies was not re-
solved. Given that topotecan reduced spontaneous, synchronous
(seizure-like) activity in mouse cortical cultures (Fig. 2), it will be
interesting to determine if TOP1 inhibitors suppress seizures in
flies via a synaptic mechanism similar the mechanism we identified
in mouse neurons. TOP1 inhibition reduces nascent RNA at the 3′
end of long, but not short, genes in Drosophila S2 cells (49), sug-
gesting that TOP1 regulates gene expression in a length-dependent
manner in flies. Thus, TOP1 could regulate neurotransmission by
facilitating long gene expression in vertebrates and invertebrates.
Intriguingly, a de novo mutation in TOP1 and mutations in genes
that interact with TOP1 were identified in patients with autism (8,
9), and these genes cluster, based on annotation criteria, with other
transcriptional regulators implicated in autism (50). Furthermore,
TOP1 cleavage complexes and DNA damage accumulate in mouse
models of the neurodegenerative syndromes ataxia telangiectasia
and spinocerebellar ataxia with axonal neuropathy (51). Cancer
patients (including children) treated with topotecan report memory
impairment and confusion suggestive of deficits in synaptic function
and neurotransmission (52–54). Thus, transient TOP1 inhibition has
the potential to impair brain function reversibly, whereas a persistent
change in TOP1 activity has the potential to disrupt neuro-
development and promote neurodegeneration. In summary, our
findings indicate that synapses are particularly vulnerable to TOP1
inhibitors and suggest that this synaptic vulnerability could have
profound effects on the developing and adult brain.
Materials and Methods
All experimental animal procedures were carried out according to the Na-
tional Institutes of Health Guide for the Care and Use of Laboratory Animals
(55) and were approved by the Institutional Animal Care and Use Committee
at the University of North Carolina at Chapel Hill. Mouse cortical neuron
culture, biochemistry, immunocytochemistry, and physiology procedures are
described in detail in SI Materials and Methods.
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